ORN-101
Pre-clinical- Indications
- Cancer
Company intelligence / Profile preview
Simnova
Shanghai, Shanghai, Chinasimnovabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Simnova has advanced multiple proprietary CAR-NK and BiTE-armed CAR-T cell therapy programs into early clinical development for hematologic malignancies and solid tumors, including Phase 1 trials for BCMA CAR-T in multiple myeloma and clinical-stage off-the-shelf CAR-NK programs; preclinical and animal model data show promising tumor suppression and persistence.[1][2][3][5][7][9]
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyCAR-NK cell therapyBiTE-armed CAR-T cell therapyOncolytic virus therapyCytokineVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Orna Therapeutics
Beyond the preview
Go deeper on Simnova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simnova.